Cost-effectiveness of Gemfibrozil for Coronary Heart Disease Patients With Low Levels of High-Density Lipoprotein CholesterolThe Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial
Open Access
- 28 January 2002
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (2) , 177-182
- https://doi.org/10.1001/archinte.162.2.177
Abstract
LOW-DENSITY lipoprotein cholesterol (LDL-C) is a risk factor for coronary heart disease (CHD), and numerous trials have shown that drugs that lower elevated LDL-C levels reduce major cardiovascular events, such as CHD death, myocardial infarction, and stroke.1-3 Approximately 40% of patients with CHD, however, do not have elevated LDL-C levels. Many of these patients instead exhibit low levels of high-density lipoprotein cholesterol (HDL-C). Because no clinical trials had determined the efficacy of lipid therapy in these patients, the US Department of Veterans Affairs (VA) conducted a multicenter randomized controlled clinical trial (the VA Cooperative Studies Program HDL-C Intervention Trial [VA-HIT]) to determine whether therapy aimed at increasing HDL-C levels and decreasing triglyceride levels would reduce major cardiovascular end points in CHD patients whose primary lipid abnormality is low HDL-C levels.4This publication has 1 reference indexed in Scilit: